Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences Inc (NQ: KZR )

0.7020 -0.0067 (-0.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 189,548
Open 0.7029
Bid (Size) 0.6815 (27)
Ask (Size) 0.7200 (7)
Prev. Close 0.7087
Today's Range 0.6911 - 0.7262
52wk Range 0.6700 - 3.130
Shares Outstanding 72,407,215
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-26.11%
-26.11%
1 Month
-13.83%
-13.83%
3 Month
-31.84%
-31.84%
6 Month
-17.89%
-17.89%
1 Year
-75.88%
-75.88%

More News

Read More
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Analyst Expectations for Kezar Life Sciences's Future
Via Benzinga
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires
Via InvestorPlace
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
Via InvestorPlace
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
Via InvestorPlace
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Via Talk Markets
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
Via InvestorPlace
3 Penny Stocks Poised for an Unbelievable 1,000% Jump
Via InvestorPlace
As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
Via InvestorPlace
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
Via Benzinga
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
From Kezar Life Sciences, Inc.
Via Business Wire
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.